Poor Results for Sanofi’s Amlitelimab, Nektar’s Shares Surge
Nektar Therapeutics’ shares took an upward turn after Sanofi unveiled preliminary results from its Phase 3 trial for its monoclonal antibody treatment for atopic dermatitis, amlitelimab. The reported outcomes, viewed as significantly below the expected efficiency threshold, also led to…
